Long QT Syndrome Panel
Use
The Long QT Syndrome Panel is designed for individuals with a clinical or suspected diagnosis of Long QT Syndrome. It is also suitable for family members of individuals diagnosed with Long QT Syndrome, and for individuals without access to the specific variant information for a family member with a genetically-confirmed case of Long QT Syndrome. The panel aids in identifying genetic mutations associated with Long QT Syndrome to facilitate diagnosis, prognosis, and familial screening.
Special Instructions
This test is available to individuals who do not have access to specific variant information of a family member but have a family member diagnosed with Long QT Syndrome. Testing includes analysis via NGS with CNV, using either Exome or Genome platforms. Additionally, Exome-wide CNV Analysis can be added to PGxome-based or custom panels as an add-on service.
Limitations
This test was developed and validated by PreventionGenetics LLC following CAP and CLIA regulations. However, the test has not been cleared or approved by the US FDA. Turnaround time for this test may vary based on the specimen type and choice of platform. Conditions outside of Long QT Syndrome may not be detected by this panel, and genetic variants of unknown significance may be reported. It is important to provide detailed clinical notes and family history to aid in variant interpretation.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
14-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided